The molecular basis for breast cancer metastasis to the brain is largely unknown 1,2 . Brain relapse typically occurs years after the removal of a breast tumour [2] [3] [4] , suggesting that disseminated cancer cells must acquire specialized functions to take over this organ. Here we show that breast cancer metastasis to the brain involves mediators of extravasation through non-fenestrated capillaries, complemented by specific enhancers of blood-brain barrier crossing and brain colonization. We isolated cells that preferentially infiltrate the brain from patients with advanced disease. Gene expression analysis of these cells and of clinical samples, coupled with functional analysis, identified the cyclooxygenase COX2 (also known as PTGS2), the epidermal growth factor receptor (EGFR) ligand HBEGF, and the a2,6-sialyltransferase ST6GALNAC5 as mediators of cancer cell passage through the blood-brain barrier. EGFR ligands and COX2 were previously linked to breast cancer infiltration of the lungs, but not the bones or liver 5, 6 , suggesting a sharing of these mediators in cerebral and pulmonary metastases. In contrast, ST6GALNAC5 specifically mediates brain metastasis. Normally restricted to the brain 7 , the expression of ST6GALNAC5 in breast cancer cells enhances their adhesion to brain endothelial cells and their passage through the blood-brain barrier. This cooption of a brain sialyltransferase highlights the role of cellsurface glycosylation in organ-specific metastatic interactions.
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Brain metastasis affects an estimated 10% of cancer patients with disseminated disease 2, 8, 9 . Even small lesions can cause neurological disability, and the median survival time of patients with brain metastasis is short. The two main sources of brain metastasis-adenocarcinomas of the lung or the breast-represent different models of the course of the disease. Metastasis from lung adenocarcinomas develops within months of diagnosis and affects several organs besides the brain 10 . This course suggests that aggressive pro-metastatic functions foster the colonization of several organs at once. In breast cancer, a long period of remission often precedes distant relapse 3, 4 , suggesting that breast cancer cells initially lack the full competence for outgrowth in distant organs but develop this under the selective pressure of different organ microenvironments. Breast cancer metastasis frequently becomes prevalent in one organ long before it does in others, and brain metastasis tends to be a late event 2 . The barriers to metastasis are distinct in different organs. Capillary endothelia are backed by a basement membrane in the lung 11 and also by tight junctions and astrocyte foot processes in the blood-brain barrier (BBB) 2, 8 , whereas the capillaries in the bone marrow and the liver are fenestrated 11, 12 . The composition of the parenchyma also varies extensively between these organs. The protracted progression of disseminated cancer cells in different environments may give rise to metastatic speciation, as suggested by the coexistence of malignant cells with different organ tropisms in fluids from patients with advanced disease 5, 13 . Analysis of such malignant cell populations has revealed genes that selectively mediate breast cancer metastasis to bones 13 or the lungs 5 .
Here we adopted this approach to test the hypothesis that breast cancer infiltration of the brain requires general mediators of extravasation, complemented by specific enhancers of cell passage through the BBB.
We used oestrogen-receptor-negative (ER
2
) pleural malignant cells from a Memorial Sloan-Kettering Cancer Center (MSKCC) breast cancer patient (CN34 sample), and also MDA-MB-231 cells (MDA231 for brevity)-an ER 2 breast cancer pleural cell line previously used for the isolation of bone and lung metastatic cells 5, 13 and brain metastatic cells 14 . CN34 and MDA231 cells were inoculated into the arterial circulation of immunodeficient female mice to isolate populations that target the brain (Fig. 1a-d) . After tumour dissociation and expansion in culture, the resulting cell populations (brain metastatic derivative 1, BrM1) were subjected to a second round of in vivo selection, yielding BrM2 cell populations that showed a significant increase in brain metastatic activity (Fig. 1a,  b) . When grown as mammary tumours, CN34-BrM2 metastasized to brain in 42% (5 out of 12) of the mice, whereas parental CN34 mammary tumours yielded no brain metastases in ten mice. BrM2 cells showed no increase in bone or lung metastatic activity compared to the parental populations (Supplementary Table 1 ). MDA231 lung metastatic (LM2-4175) and bone metastatic (BoM-1833; refs 5, 13) derivatives were poorly metastatic to brain compared to BrM2 cells (Fig. 1b) . The CN34-BrM2 and MDA231-BrM2 cell lines generated multifocal lesions in the cerebrum, the cerebellum and the brainstem (Fig. 1e, f and Supplementary Fig. 1a, b) , and in the leptomeninges ( Fig. 1g and Supplementary Fig. 1c, d ). Larger nodules developed hemorrhagic cores and oedema (Fig. 1d) . Astrogliosis occurred in the periphery of the tumours (Fig. 1h) . All of these features are typical of brain metastasis in breast cancer patients 2, 15 . Within 24 h of inoculation, BrM2 cells lodged in brain capillaries as single cells (Fig. 1i) , suggesting that brain metastases resulted from an ability of these cells to breach the BBB.
Comparative genome-wide expression analysis demonstrated 243 genes that were overexpressed or underexpressed in the brain metastatic populations of both cell lines, or were upregulated in one cell system and overexpressed in the other, or were downregulated in one system and underexpressed in the other (Supplementary Table 2 ). To prioritize these candidate genes, we screened for those whose expression in breast tumours was associated with brain relapse. Univariate analysis in a combined cohort of 368 clinically annotated breast tumours (MSK-82 and EMC-286 sets; Supplementary Table 3) showed 17 genes whose expression was correlated (P , 0.05) with brain relapse (Supplementary Table 4) , and resembled the expression profile in the brain-metastatic-derived (BrM) cells ( Supplementary  Fig. 2a, b) . A classifier trained with this brain metastasis gene set (BrMS) showed association with brain relapse in two independent breast tumour data sets ( Fig. 2a and Supplementary Fig. 3a) . The same procedures applied to randomly generated sets of 500 genes yielded no classifiers that performed in the data sets. The association of BrMS status with brain relapse remained significant within ER 2 tumours (Supplementary Table 5 and Supplementary Fig. 3b ), and was stronger in patients who received no adjuvant therapy (P , 0.0001; Fig. 2b and Supplementary Table 6 ). BrMS 1 tumours appeared in different molecular subtypes of breast cancer 16 ( Supplementary Fig. 4a-c) .
We do not interpret the results of the gene expression analysis as reflecting the only possible 17 genes associated with brain relapse. However, the expression of these 17 genes in breast tumours was not associated with relapse to bones, liver or lymph nodes ( Supplementary  Fig. 5a ). Notably, six of these genes were shared with an 18-gene lung metastasis signature (LMS) that is associated with relapse to the lungs, but not to bones, liver or lymph nodes 17 . LMS 1 status was weakly associated with relapse to the brain, and BrMS 1 status with relapse to the lungs ( Supplementary Fig. 5b-d) . The shared genes include the prostaglandin-synthesizing enzyme cyclooxygenase-2 (COX2), which promotes extravasation in the lungs 6 ; collagenase-1 (MMP1), which mediates invasion and extravasation 6, 18 ; angiopoietin-like 4 (ANGPTL4), which is induced by tumour-derived TGF-b and disrupts endothelial junctions 19 ; latent TGF-b-binding protein (LTBP1), which controls TGF-b activation 20 ; fascin-1 (FSCN1), which supports cancer cell migration 21 ; and the putative metastasis suppressor RARRES3 (ref. 5). Furthermore, both gene sets include an EGFR ligand: heparin-binding EGF (HBEGF) in the BrMS, and epiregulin (EREG) in the LMS. EREG was highly expressed in CN34-BrM but not in MDA231-BrM cells.
These observations suggested a partial sharing of mediators of metastasis to the brain and lungs, a hypothesis that we tested by focusing on EGFR ligands and COX2. Prostaglandin production during inflammation increases BBB permeability 22 . HBEGF induces cancer cell motility and invasiveness 23 . The brain metastatic activity of BrM2 cells (Fig. 2c, d ) was decreased by RNA interference (RNAi)-mediated knockdown of COX2 expression 6 ( Supplementary Fig. 6a,  b) , or by treatment of mice with cetuximab, which targets human EGFR 24 . To investigate cancer cell passage through the BBB, we used an in vitro model consisting of human primary endothelial cells and astrocytes ( Fig. 2e and Supplementary Fig. 7a ). This model generates a tight barrier that expresses brain endothelial markers and lacks permeability to albumin ( Supplementary Fig. 7b-d ) 25 . CN34-BrM2 and MDA231-BrM2 cells were three-to fourfold more active than their parental lines at migrating through this barrier. COX2 knockdown inhibited this transmigration in both BrM2 lines, as did the addition of cetuximab to CN34-BrM2 cells, or the combination of COX2, HBEGF and EREG knockdowns ( Fig. 2f and Supplementary  Fig. 7e ).
The ability of COX2 and EGFR ligands to prime breast cancer cells for extravasation into the brain may explain the association of lung and brain relapse in breast cancer 9, 26 . However, given the course of breast cancer, we postulated that brain relapse also depends on selective mediators of infiltration through the unique barriers of the brain. As candidates we selected genes whose expression was increased more than threefold in all CN34-BrM2 and MDA231-BrM2 isolates, but not in bone metastatic 13 or lung metastatic MDA231 derivatives 5 . After excluding histone genes, we arrived at a set of 26 candidates (Supplementary Table 7 ). This set largely consists of cell-cell interaction components. The a2,6-sialyltransferase ST6GALNAC5 stood out because its expression is normally restricted to the brain both in mice 7 and in humans ( Supplementary Fig. 8 ). ST6GALNAC5 messenger RNA levels were notably higher in brain metastatic derivatives than in parental cell lines in MDA231 samples (30-fold 6 1 higher; mean 6 s.d.), CN34 cells (.100-fold), and in two other pleural-derived samples that were subjected to one cycle of selection for brain infiltration in mice (CN37-BrM1, 95-fold 6 23; CN41-BrM1, 72-fold 6 12).
Sambucus nigra agglutinin (SNA), a lectin that binds to a2,6-linked sialyl groups, specifically stained mammary tumours and brain lesions formed by BrM2 cells (Fig. 3a, b and Supplementary  Fig. 9a, b) . Fifty per cent (6 out of 12) of brain metastatic samples from breast cancer patients had areas with strong SNA staining, whereas 18% (2 out of 11) of lung metastatic samples had areas of low SNA staining, and the remaining 9 samples were negative (Fig. 3c,  d) . Furthermore, in a set of ER 2 breast cancer metastasis to various sites, ST6GALNAC5 mRNA levels roughly equalled that of the BrM2 cell lines in 23% (3 out of 12) of brain metastases, but not in metastases to other sites ( Fig. 3e ; P 5 0.04, Fisher's exact test).
Sialyltransferases catalyse the addition of sialic acid to gangliosides and glycoproteins 27 , and cell-surface sialylation has been implicated in cell-cell interactions 28 . CN34-BrM2 cells were more adhesive to monolayers of human primary brain endothelial cells than were the CN34 or ST6GALNAC5-knockdown CN34-BrM2 cells (Supplementary Fig. 10a) . Notably, the knockdown of ST6GALNAC5 decreased the BBB transmigration activity of CN34-BrM2 cells to ground level (Fig. 4a) , and also decreased the brain metastatic activity of CN34-BrM2 cells (Fig. 4b) . Brain metastasis was further decreased by combination with cetuximab treatment (Fig. 4b) . ST6GALNAC5 knockdown did not inhibit the growth of CN34-BrM2c cells in culture or as mammary tumours, the basal lung-seeding ability of these cells, or the aggressive lung-colonizing ability of the MDA231 derivative Fig. 10b-f) . However, transduction of LM2-4175 cells with an ST6GALNAC5 expression vector increased the ability of these cells to transmigrate across a BBB (Fig. 4c) and to infiltrate the brain (Supplementary Fig. 11a ). Infiltrated brains showed a prevalence of micrometastases in mice inoculated with LM2-ST6 and of larger lesions in mice inoculated with BrM2 cells (Fig. 4d and Supplementary Fig. 11b ). ST6GALNAC5 therefore mediates infiltration into the brain, and further mediators may be required for the expansion of the resulting foci into macrometastases.
Breast cancer cells can disseminate to the lungs from early stages of tumour development 29 , indicating that cancer cells departing from breast tumours are competent for extravasation through lung microcapillary walls. Our results indicate that the expression of COX2 and HBEGF in primary tumours enhances cancer cells for extravasation through the non-fenestrated capillaries of the brain and lungs, whereas ST6GALNAC5 expression is co-selected with, and acts as a specific mediator of, cancer cell infiltration through the blood-brain (Fig. 4e) . These findings draw attention to the role of cellsurface sialylation as a previously unrecognized participant in brain metastasis, and to the possibility of therapeutically disrupting these interactions. Our work also points to other candidate brain metastasis genes, including genes implicated in vascular permeability and leukocyte infiltration during brain inflammatory processes, and genes implicated in neurite extension and astrocyte cell processes. The role of these genes in brain metastasis and their interest as therapeutic targets is open to further analysis.
METHODS SUMMARY
CN34 tumour cells were isolated from the pleural effusion of a breast cancer patient treated at our institution, after written consent in accordance with Institutional Review Board (IRB) regulations. Brain metastatic populations from these cells and MDA-MB-231 cells were obtained by consecutive rounds of in vivo selection in 6-7-week-old beige nude and athymic mice, respectively. All animal work was done in accordance with the MSKCC Institutional Animal Care and Use Committee. Methods for RNA extraction, labelling and hybridization for DNA microarray analysis have been described previously 17 . Bioinformatics analyses with detailed descriptions can be found in the Methods. Knockdown and overexpression of candidate genes, and cetuximab inhibitor studies were performed as previously described 6 . The in vitro BBB model was set up as previously described 25 , and modified to enable tumour cell counting. Sambucus nigra lectin staining was performed using standard histochemical techniques, and quantified using Metamorph software analysis. The Methods section provides further information, including malignant cell isolation from pleural fluids, tumour cell extraction and cell culture protocols, animal inoculation and bioluminescence imaging, generation of retroviral gene knockdown and overexpression vectors, transfections and infections, RNA and protein expression, in vitro BBB transmigration assay, endothelial cell adhesion assay, and metastatic tissue staining and quantification.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
METHODS
Isolation of carcinoma cells from pleural effusions. Clinical specimens were obtained from three consenting patients (CN34, CN37 and CN41) with metastatic breast cancer treated at our institution, following IRB-approved protocols. Epithelial cells were obtained from pleural fluids as described before 30 . In brief, pleural fluid was collected in the presence of heparin (5 U ml 21 ), and centrifuged at 150g for 10 min. Cell pellets were resuspended in PBS, red blood cells were lysed with ACK lysis buffer, and a fraction of the cells was subjected to negative selection to remove leukocytes (CD45 1 and CD15 1 populations). Cells were cultured for 24 h, and epithelial cells were sorted from this population using an anti-EpCAM antibody. The resulting cell population was transduced with a lentivirus expressing the triple-fusion reporter encoding herpes simplex virus thymidine kinase 1, GFP and firefly luciferase 31 . GFP-expressing cells were sorted and maintained at 5% CO 2 at 37 uC in M199 medium supplemented with 2.5% fetal bovine serum (FBS), 10 mg ml 21 insulin, 0.5 mg ml 21 hydrocortisone, 20 ng ml 21 EGF, 100 ng ml 21 cholera toxin, 1 mg ml 21 fungizone, and 100 U ml 21 penicillin/streptomycin, for approximately 1 week before mouse injection. Isolation of brain metastatic cells. A cell suspension containing 10 5 CN34 breast cancer cells in a volume of 100 ml was injected in the left cardiac ventricle of anesthetized 6-7-week-old Cr:NIH-bg-nu-Xid mice. A cell suspension of 10 4 MDA-MB-231 breast cancer cells in a volume of 100 ml was injected in the left cardiac ventricle of anesthetized 6-7-week-old athymic mice. Tumour development was monitored by weekly bioluminescence imaging using the IVIS-200 imaging system from Xenogen as previously described 5 . Brain metastatic lesions were confirmed by MRI and histological analysis after necropsy. Brain lesions were localized by ex vivo bioluminescence imaging, and resected under sterile conditions. Half of the tissue was fixed with 4% paraformaldehyde (PFA), and processed for histological analysis. The other half was minced and placed in culture medium containing a 1:1 mixture of DMEM/Ham's F12 supplemented with 0.125% collagenase III and 0.1% hyaluronidase. Samples were incubated at room temperature for 4-5 h, with gentle rocking. After collagenase treatment, cells were briefly centrifuged, resuspended in 0.25% trypsin, and incubated for a further 15 min in a 37 uC water bath. Cells were resuspended in culture medium and allowed to grow to confluence on a 10-cm dish. GFP 1 cells were sorted for further propagation in culture or inoculation in mice. All animal work was done following a protocol approved by the MSKCC Institutional Animal Care and Use Committee. Histological analysis and microscopy. Brain metastatic lesions were fixed with 4% PFA overnight, washed twice with PBS, dehydrated in 50% ethanol, and subsequent 70% ethanol, and embedded in paraffin for H&E staining. For all other purposes, animals were perfused with 10 ml PBS, and pre-fixed with 5 ml of 4% PFA. Lesions were extracted and post-fixed with 4% PFA for a further 2 h, incubated in a solution of 30% sucrose in PBS for 1-2 days, and processed for OCT compound embedding and montage. Assessment of reactive glia was performed by staining with the astrocyte marker GFAP (DAKO), followed by detection with a fluorescently labelled secondary antibody. Detection of tumour foci in the brain parenchyma was achieved by immunohistochemistry using an anti-GFP antibody (Invitrogen). For this purpose, the brain hemispheres were separated longitudinally and mounted in OCT. Four sections from each hemisphere were obtained, separated by 300 mm. In total, eight brain regions were stained with anti-GFP and microscopically explored using 35 magnification. Microscopic analysis was performed using a Zeiss Axioplan2 microscope, and foci quantification was achieved using Metamorph software analysis. For detection of tumour cells in the brain microvasculature, 10 6 brain metastatic cells were injected into the left cardiac ventricle of anesthetized mice. Enhancement of the green fluorescence was obtained by labelling the tumour cells with 5 mM CFMDA cell-tracker dye (Invitrogen) for 45 min before injection. To visualize the brain vasculature, mice were injected with 2 mg g 21 of body weight rhodaminelabelled 70-kDa dextran (Invitrogen) via retro-orbital inoculation 1 h before culling. Animals were perfused and culled 24 h after tumour cell inoculation, and brain was processed for OCT compound embedding. Thirty-micrometre sections were examined on an Upright Leica TCS SP2 confocal microscope, and 363 images were collected. RNA isolation and gene-expression profiling. RNA was extracted from exponentially growing cells using the RNeasy mini kit (Qiagen). Labelling and hybridization of the samples to HG-U133A gene expression chip (Affymetrix) were performed by the MSKCC Genomics Core Facility using standard methodology, as previously described 17 . Data analysis was performed using the GeneSpring 7.2 software. The raw data was filtered by intensity values equal to or greater than 150. Class comparison between parental and brain metastatic populations (three biological replicates of the MDA231 parental versus four brain metastatic derivatives, and two biological replicates of CN34 parental versus four brain metastatic derivatives) was performed to identify gene expression changes of 2.5-fold associated with the brain metastatic phenotype (P , 0.05). This step yielded 271 genes (310 probe sets) that were differentially expressed between the parental and the brainmetastatic CN34 cell lines, and 179 genes (210 probe sets) between the parental and the brain-metastatic MDA231 cell lines. From these lists, we selected genes with a concordant expression change of at least 1.5-fold in the other cell system, genes that were upregulated in one system and consistently expressed at a high level in the other, and genes that were downregulated in one system and consistently underexpressed in the other. As a result, we obtained a final list of 280 probe sets, corresponding to 243 genes that are associated with brain metastatic phenotype in CN34 and MDA231 cells (Supplementary Table 2 ). BrMS derivation and clinical sample analysis. Microarray data from four cohorts of breast tumours were used for analysis. The MSK-82 cohort was more locally advanced compared to either the NKI-295 or the EMC-286 series (91% T2-T4 and 66% node positive in MSK-82, compared to 47% T2-T4 and 49% node positive in NKI-295, and 51% T1, 46% T2 and 0% node positive in EMC-286). EMC-192 is a heterogeneous cohort that includes 144 tumours from patients that relapsed and received first-line chemotherapy for metastatic disease in an adjuvant or recurrence setting, and 48 from patients that were nodenegative and did not receive adjuvant systemic therapy. Sites of recurrence and treatment information for each of these data sets are shown in Supplementary Table 3 .
The MSK-82 and EMC-286 cohorts were analysed on Affymetrix HG-U133A platform, and the EMC-192 cohort on HG-U133 plus 2.0. The NKI-295 set was analysed on Agilent microarrays. To achieve statistical power given the limited incidence of brain metastasis in these cohorts, we merged the MSK-82 and EMC-286 cohorts. All data sets were first transformed to log-2 scales and mediancentred. Z transformation was then performed to normalize gene expression across all samples in each cohort, using the MAS5.0 normalization approach 32 . The 243 gene set (280 probe set) associated with brain metastasis was used to fit a Cox hazard ratio regression model to gauge the association of each gene with brain or lung metastasis-free survival in the combined MSK-82/EMC-286 cohort. This was achieved using the survival package in the R statistical software. Wald test was used to calculate the P values. We designated 'brain metastasis gene set' (BrMS) the 17 genes with P , 0.05 from the 243 gene set. To examine whether these 17 genes were obtained owing to artefactual effects caused by merging the MSK-82 and EMC-286 cohorts, we performed principal component analysis and tested whether the two data sets differentially distributed along the top two principal components (Supplementary Fig. 12 ). This analysis revealed no segregation between the two data sets (P 5 0.11 and 0.28 for the top two principal components by t-test) ( Supplementary Fig. 9 ), arguing that the statistical significance and classification power of the 17 genes cannot be attributed to the merge of the two data sets. The identification of BrMS 1 tumours was achieved by unsupervised hierarchical clustering of tumours in the MSK-82 and EMC-286 as a training cohort. The resulting cluster-tree was cut at different distance cutoffs to yield different numbers (2 to 10) of sub-clusters. In each case, the cluster that most resembled the gene expression pattern of BrM cells was compared with the other clusters for enrichment of brain relapse events, using Fisher's exact test. The best cutoff was determined when such cluster not only maintained the resemblance of gene expression pattern to BrM cells, but also best-segregated brain relapse events. This cluster was defined as BrMS 1 . Heat maps were generated using the gplots package of R statistical program.
For each patient, metastasis-free survival is defined as the time interval between the surgery and the diagnosis of metastasis. When there are several metastatic sites, because the chronological order of different metastatic sites on the same patient was not annotated, it has been assumed that all metastases were diagnosed at the same time, and each patient was scored for each of the corresponding sites in our analyses. BrMS 1 and BrMS 2 tumours were used to train a support vector machine (package e1071, R statistical program). We used a linear kernel and expression values of the 17-gene BrMS as features. The trained classifier was then applied to the NKI-295 and EMC-192 cohorts to predict BrMS 1 tumours. We performed Kaplan-Meier analysis and log-rank tests on the survival rates of the predicted BrMS 1 and BrMS 2 tumours in the NKI-295 and EMC-192 data sets, using the survival package of R. The specificity and sensitivity of the BrMS and LMS classifiers as predictors of brain metastatic recurrence is shown in Supplementary Table 6 .
As a control, we randomly generated ten sets of 500 genes each, and determined the correlation of the genes in each set with brain metastasis-free survival in the 368-tumour cohort. We then selected univariately significant genes, trained classifiers using EMC/MSK-368 and tested the classifiers on the independent EMC192 and NKI295 data sets as we did with the BrMS. Such randomly derived classifiers yielded P values for brain relapse association ranging from 0.1
